Acadian Asset Management LLC Vir Biotechnology, Inc. Transaction History

Acadian Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$7.76 - $10.29 $1.12 Million - $1.49 Million	-144,381 Reduced 98.17%	2,692 $27,000
Q3 2023 Nov 13, 2023	SELL	$9.14 - $24.62 $159,127 - $428,634	-17,410 Reduced 10.58%	147,073 $1.38 Million
Q2 2023 Aug 07, 2023	SELL	$23.2 - $27.29 $271,741 - $319,647	-11,713 Reduced 6.65%	164,483 $4.03 Million
Q1 2023 May 11, 2023	BUY	$22.26 - $30.85 $1.49 Million - $2.07 Million	67,103 Added 61.51%	176,196 $4.1 Million
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $1.8 Million - $2.55 Million	-90,324 Reduced 45.29%	109,093 $2.76 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $1.03 Million - $1.75 Million	56,168 Added 39.21%	199,417 $3.84 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $1.03 Million - $1.75 Million	56,168 Added 39.21%	199,417 $3.84 Million
Q2 2022 Aug 09, 2022	BUY	$19.08 - $26.7 $2.59 Million - $3.62 Million	135,531 Added 1756.04%	143,249 $3.65 Million
Q1 2022 May 12, 2022	BUY	$21.19 - $40.01 $163,544 - $308,797	7,718 New	7,718 $197,000
Q4 2021 Feb 10, 2022	SELL	$30.97 - $54.03 $144,165 - $251,509	-4,655 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$34.9 - $54.54 $162,459 - $253,883	4,655 New	4,655 $200,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $944M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.